<< Back
Inovio Biomedical CEO Addresses MIT's Emerging Technologies Conference

Dr. J. Joseph Kim Highlights Inovio's Universal DNA Vaccine Approach to Prevent and Treat Infectious Diseases Including Influenza

SAN DIEGO--(BUSINESS WIRE)--Sep. 24, 2009-- Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today that Dr. J. Joseph Kim, Inovio’s CEO, presented keynote remarks at MIT’s Emerging Technologies Conference hosted by the Massachusetts Institute of Technology. (Read Dr. Kim’s speech.)

The conference, which took place this week in Boston, annually attracts top decision makers from companies in global business sectors ranging from technology and engineering to investment and management consulting.

Dr. Kim’s speech, titled “The Promise of DNA Vaccines: A New Approach to Vaccine Design, Drug Delivery and Disease Prevention,” focused on the advantages of DNA vaccines versus traditional therapies, highlighting their promise of enhanced speed of development, ease of manufacture, and broader immune responses, as well as the “designer” nature of Inovio’s novel vaccine approach. He discussed how Inovio’s DNA vaccine delivery technology is showing the potential to overcome barriers that slowed the development of DNA vaccines in the past. Inovio's universal vaccines have shown preclinical results indicating their ability to protect against new, unmatched strains of infectious diseases including the currently circulating “swine” flu. Inovio is also developing vaccines against HIV, HPV and cancer, with several studies currently in clinical trials.

About Inovio Biomedical Corporation

Inovio Biomedical is engaged in the design, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The company’s SynCon™ technology enables the design of DNA-based vaccines capable of providing cross-protection against new, unmatched strains of pathogens such as influenza. Inovio’s proprietary electroporation-based DNA vaccine delivery technology has been shown by initial human data to safely and significantly increase gene expression and immune responses. Inovio’s clinical programs include HPV/cervical cancer (therapeutic) and HIV vaccines. An IND has been filed for an avian influenza vaccine. Inovio is developing its universal and avian influenza vaccines in collaboration with scientists from the University of Pennsylvania and the National Microbiology Laboratory of the Public Health Agency of Canada. Other partners and collaborators include Merck, Tripep, University of Southampton, National Cancer Institute and HIV Vaccines Trial Network. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company’s combined technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2008, our Form 10-Q for the six months ended June 30, 2009, and other regulatory filings from time to time. There can be no assurance that any product in Inovio’s pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

Source: Inovio Biomedical Corporation

Inovio Biomedical
Bernie Hertel, 858-410-3101
Richardson & Associates
Jeff Richardson, 805-491-8313

Could not find file '\\pro.dianum.io\irwebpro\content3\IRXMLDATA\10\105128\Disclaimers.xml'.